Asbestos activates CH12.LX B-lymphocytes via macrophage signaling

Journal of Immunotoxicology

Volumn 9, Issue 2, 2012, Pages 129-140

  Rasmussen, Devon L ^a   Pfau, Jean C ^a  

^a Nucl Eng Idaho State University   (United States)

Author keywords

B1a B lymphocytes; IL 6; TNF

Indexed keywords

ASBESTOS; AUTOANTIBODY; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL LINE; CELL SURFACE; CH12.LX B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENVIRONMENTAL EXPOSURE; EX VIVO STUDY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ASBESTOS, AMPHIBOLE; ASBESTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; CARCINOGENS; CELL LINE; CELL PROLIFERATION; IMMUNOGLOBULIN ISOTYPES; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

MURINAE; MUS;

EID: 84861058421     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2011.631953     Document Type: Article

References (61)

1. Arnold L. W., Locascui N. J., Lutz P. M., Pennell C. A., Klapper D., and Haughton G. 1983. Antigen-induced lymphomagenesis: Identification of a murine B-cell lymphoma with known antigen specificity. J. Immunol. 131:2064-2068.
2. Baker N., and Ehrenstein M. R. 2002. Cutting edge: Selection of B-lymphocyte subsets is regulated by natural IgM. J. Immunol. 169:6686-6690.
3. Bao S., Husband A. J., and Beagley K. W. 1999. B1 B-cell numbers and antibodies against phosphorylcholine and LPS are increased in IL-6 gene knockout mice. Cell. Immunol. 198:139-142.
4. Baudino L., Azeredo Da Silveira S., Nakata M., and Izui S. 2006. Molecular and cellular basis for pathogenicity of autoantibodies: Lessons from murine monoclonal auto-Antibodies. Springer Semin. Immunopathol. 28:175-184.
5. Baumgarth N., Herman O. C., Jager G. C., Brown L. E., Herzenberg L. A., and Chen J. 2000. B-1 and B-2 cell-derived IgM antibodies are non-redundant components of the protective response to influenza virus infection. J. Exp. Med. 192:271-280.
6. Berland R., and Wortis H. H. 2003. Normal B-1a cell development requires B-cell-intrinsic NFATc1 activity. Proc. Natl. Acad. Sci. USA 100:13459-13464.
7. Bishop G. A., McMillan M. S., Haughton G., and Frelinger J. A. 1988. Signaling to a B-cell clone by Ek, but not Ak, does not reflect alteration of Ak genes. Immunogenetics 28:184-192.
8. Blake D. J., Bolin C. M., Cox D. P., Cardozo-Pelaez F., and Pfau J. C. 2007. Internalization of Libby amphibole asbestos and induction of oxidative stress in murine macrophages. Toxicol. Sci. 99:277-288.
9. Casali P., Burastero S. E., Nakamura M., Inghirami G., and Notkins A. L. 1987. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 236:77-81.
10. Cunningham H. M., and Pontefract R. D. 1973. Asbestos fibers in beverages, drinking water, and tissues: Their passage through the intestinal wall and movement through the body. J. Assoc. Off. Anal. Chem. 56:976-986.
11. Defanco A. L., Kung J. T., and Paul W. E. 1982. Regulation of growth and proliferation in B-cell subpopulations. Immunol. Rev. 64:161-182.
12. Dodson R. F., Williams M. G., Corn C. J., Brollo A., and Bianchi C. 1991. A comparison of asbestos burden in lung parenchyma, lymph nodes, and plaques. Ann. N.Y. Acad. Sci. 643:53-60.
13. Duan B., and Morel L. 2006. Role of B-1a cells in autoimmunity. Autoimmun. Rev. 5:403-408.
14. Esplin B. L., Welner R. S., Zhang Q., Borghesi L. A., and Kincade P. W. 2009. A differentiation pathway for B1 cells in adult bone marrow. Proc. Natl. Acad. Sci. USA 106:5773-5778.
15. Fulpius T., Spertini F., Reininger L., and Izui S. 1993. Immunoglobulin heavy chain constant region determines the pathogenicity and the antigen-binding activity of rheumatoid factor. Proc. Natl. Acad. Sci. USA 90:2345-2349.
16. Gigante A., Gasperini M. L., Afeltra A., Barbano B., Margiotta D., Cianci R., De Francesco I., and Amoroso A. 2011. Cytokines expression in SLE nephritis. Eur. Rev. Med. Pharmacol. Sci. 15:15-24.
17. Grivennikov S. I., and Karin M. 2011. Inflammatory cytokines in cancer: Tumor necrosis factor and interleukin-6 take the stage. Ann. Rheum. Dis. 70(Suppl 1):i104-i108.
18. Guerne P. A., Zuraw B. L., Vaughan J. H., Carson D. A., and Lotz M. 1989. Synovium as a source of IL-6 in vitro. Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83:585-592.
19. Gunter M. E., Dyar M. D., Twamley B., Foit F. F., and Cornelius S. 2003. Composition, Fe3+/Sigma Fe, and crystal structure of nonasbestiform and asbesti-form amphiboles from Libby, Montana, USA. Amer. Mineralogist 88:1970-1978.
20. Hamano Y., Hirose S., Ida A., Abe M., Zhang D., Kodera S., Jiang Y., Shirai J., Miura Y., Nishimura H., and Shirai T. 1998. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneouslyoccurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. Blood 92:3772-3779.
21. Hardy R. R., Hayakawa K., Shimizu M., Yamasaki K., and Kishimoto T. 1987. Rheumatoid factor secretion from human Leu-1+ B-cells. Science 236:81-83.
22. Hata H., Sakaguchi N., Yoshitomi H., Iwakura Y., Sekikawa K., Azuma Y., Kanai C., Moriizumi E., Nomura T., Nakamura T., and Sakaguchi S. 2004. Distinct contribution of IL-6, TNFa, IL-1, and IL-10 to T-cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114:582-528.
23. Hayakawa K., Hardy R. R., and Herzenberg L. A. 1986. Peritoneal Ly-1 B-cells: Genetic control, autoantibody production, increased lambda light chain expression. Eur. J. Immunol.16:450-456.
24. Hayakawa K., Hardy R. R., Honda M., Herzenberg L. A., and Steinberg A. D. 1984. Ly-1 B-cells: Functionally-distinct lymphocytes that secrete IgM autoantibodies. Proc. Natl. Acad. Sci. USA 81:2494-2498.
25. Hillion S., Dueymes M., Youinou P., and Jamin C. 2007. IL-6 contributes to the expression of RAGs in human mature B-cells. J. Immunol. 179:6790-6798.
26. Jones B. M. 1996. Effect of 12 neutralizing anti-cytokine antibodies on in vitro activation of B-cells. Interleukin-12 is required by B1a but not B2 cells. Scand. J. Immunol. 43:64-72.
27. Karampetsou M. P., Andonopoulos A. P., and Liossis S. N. 2011. Treatment with TNFa blockers induces phenotypical and functional aberrations in peripheral B-cells. Clin. Immunol. 140:8-17.
28. Kendall P. L., Woodward E. J., Hulbert C., and Thomas J. W. 2004. Peritoneal B-cells govern the outcome of diabetes in non-obese diabetic mice. Eur. J. Immunol. 34:2387-2395.
29. Kishimoto T., and Hirano T. 1988. Molecular regulation of B-lymphocyte response. Annu. Rev. Immunol. 6:485-512.
30. Kroese F. G., Ammerlaan W. A., and Kantor,A. B. 1993. Evidence that intestinal IgA plasma cells in μ transgenic mice are derived from B-1 (Ly-1 B) cells. Int. Immunol. 5:1317-1327.
31. Kroese F. G., Butcher E. C., Stall A. M., Lalor P. A., Adams S., and Herzenberg L. A. 1989. Many of the IgA-producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int. Immunol. 1:75-84.
32. Kuzin I., Ugine G. D., Barth R. K., Shultz L. D., Nahm M. H., Young F. M., and Bottaro A. 2004. A new murine model of humoral immunodeficiency specifically affects class switching to T-independent antigens. Eur. J. Immunol. 34:1807-1816.
33. Lange A. 1980. An epidemiological survey of immunological abnormalities in asbestos workers. I. Non-organ and organspecific autoantibodies. Environ. Res. 22:162-175.
34. Liang B., Gardner D. B., Griswold D. E., Bugelski P. J., and Song X. Y. 2006. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119:296-305.
35. Linker-Israeli M., Deans R. J., Wallace D. J., Prehn J., Ozeri-Chen T., and Klinenberg J. R. 1991. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147:117-123.
36. McConnell E. E., Axten C., Hesterberg T. W., Chevalier J., Miller W. C., Everitt J., Oberdorster G., Chase G. R., Thevenaz P., and Kotin P. 1999. Studies on the inhalation toxicology of two fiberglasses and amosite asbestos in the Syrian golden hamster. Part II. Results of chronic exposure. Inhal. Toxicol. 11:785-835.
37. McGinnes K., and Paige C. J. 1991. Interleukins-1, -4, and -6 induce the colony formation of human bone marrow B lineage cells. Eur. J. Immunol. 21:1271-1275.
38. Meeker G. P., Bern A. M., Brownfield I. K., Lowers H. A., Sutley S. J., Hoefen T. M., and Vance J. S. 2003. The composition and morphology of amphiboles from the Rainy Creek complex, near Libby, Montana. Amer. Mineralogist. 88:1955-1969.
39. Mohan C., Morel L., Yang P., and Wakeland E. K. 1998. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum. 41:1652-1662.
40. Murakami M., and Honjo T. 1995. B-1 cells and autoimmunity. Ann. N.Y. Acad. Sci. 764:402-409.
41. Murakami M., Yoshioka H., Shirai T., Tsubata T., and Honjo T. 1995. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int. Immunol. 7:877-882.
42. Nakamura M., Kondo S., Sugai M., Nazarea M., Imamura S., and Honjo T. 1996. High frequency class switching of an IgM+ B-lymphoma clone CH12F3 to IgA+ cells. Int. Immunol. 8:193-201.
43. Nigam S. K., Suthar A. M., Patel M. M., Karnik A. B., Dave S. K., Kashyap S. K., and Venkaiah K. 1993. Humoral immunological profile of workers exposed to asbestos in asbestos mines. Indian J. Med. Res. 98:274-277.
44. Niklinski J., Niklinska W., Chyczewska E., Laudanski J., Naumnik W., Chyczewski L., and Pluygers E. 2004. The epidemiology of asbestosrelated diseases. Lung Cancer 45(Suppl 1):S7-S15.
45. Noonan C. W., Pfau J. C., Larson T. C., and Spence M. R. 2006. Nested case-control study of autoimmune disease in an asbestos-exposed population. Environ. Health Perspect. 114:1243-1247.
46. North C. M., Crawford R. B., Lu H., and Kaminski N. E. 2010. 2,3,7,8-Tetrachloro-dibenzo-p-dioxin-mediated suppression of toll-like receptor stimulated B-lymphocyte activation and initiation of plasmacytic differentiation. Toxicol. Sci.116:99-112.
47. Peipins L. A., Lewin M., Campolucci S., Lybarger J. A., Miller A., Middleton D., Weis C., Spence M., Black B., and Kapil V. 2003. Radiographic abnormalities and exposure to asbestoscontaminated vermiculite in the community of Libby, Montana, USA. Environ. Health Perspect. 111:1753-1759.
48. Pfau J. C., Sentissi J. J., Li S., Calderon-Garciduenas L., Brown J. M., and Blake D. J. 2008. Asbestos-induced autoimmunity in C57BL/6 mice. J. Immunotoxicol. 5:129-137.
49. Pfau J. C., Sentissi J. J., Weller G., and Putnam E. A. 2005. Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA. Environ. Health Perspect. 113:25-30.
50. Powell J. J., Van de Water R. J., and Gershwin M. E. 1999. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ. Health Perspect. 107(Suppl 5):667-672.
51. Resnick D., Freedman N. J., Xu S., and Krieger M. 1993. Secreted extracellular domains of macrophage scavenger receptors form elongated trimers which specifically bind crocidolite asbestos. J. Biol. Chem. 268:3538-3545.
52. Sabry A., Sheashaa H., El-Husseini A., Mahmoud K., Eldahshan K. F., George S. K., Abdel-Khalek E., El-Shafey E. M., and Abo-Zenah H. 2006. Pro-inflammatory cytokines (TNFa and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine 35:148-153.
53. Schioppa T., Moore R., Thompson R. G., Rosser E. C., Kulbe H., Nedospasov S., Mauri C., Coussens L. M., and Balkwill F. R. 2011. B-regulatory cells and the tumor-promoting actions of TNFa during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 108:10662-10667.
54. Snir A., Kessel A., Haj T., Rosner I., Slobodin G., and Toubi E. 2011. Anti-IL-6 receptor antibody (tocilizumab): A B-cell targeting therapy. Clin. Exp. Rheumatol. 29:697-700.
55. Tarlinton D. M., McLean M., and Nossal G. J. 1995. B1 and B2 cells differ in their potential to switch immunoglobulin isotype. Eur. J. Immunol. 25:3388-3393.
56. Tossavainen A., Karjalainen A., and Karhunen P. J. 1994. Retention of asbestos fibers in the human body. Environ. Health Perspect. 102(Suppl 5):253-255.
57. Whitmore A. C., Prowse D. M., Haughton G., and Arnold L. W. 1991. Ig isotype switching in B-lymphocytes. The effect of T-cell-derived interleukins, cytokines, cholera toxin, and antigen on isotype switch frequency of a cloned B-cell lymphoma. Int. Immunol. 3:95-103.
58. Wylie A. G., and Verkouteren J. R. 2000. Amphibole asbestos from Libby, Montana: Aspects of nomenclature. Amer. Mineralogist 85:1540-1542.
59. Zerva L. V., Constantopoulos S. H., and Moutsopoulos H. M. 1989. Humoral immunity alterations after environmental asbestos exposure. Respiration 55:237-241.
60. Zhang M., and Carroll M. C. 2007. Natural antibody-mediated innate autoimmune response. Mol. Immunol. 44:103-110.
61. Zhang M., Michael L. H., Grosjean S. A., Kelly R. A., Carroll M. C., and Entman M. L. 2006. The role of natural IgM in myocardial ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 41:62-67.